Skip to main content

Advertisement

SpringerLink
Log in

The Management of Asymptomatic Skeletal Breast Cancer: A Paradigm Shift

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Cancer Trends Progress Report—2005 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, December 2005. Available: http://progressreport.cancer.gov [accessed February 4, 2007]

  2. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumour improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006; 18:2743–9

    Article  Google Scholar 

  3. Van der Linden YM, Dijkstra SPDS, Vonk EJA, Marijnen CAM, Leer JWH. Prediction of survival in patients with metastases in the spinal column. Results based on a randomized trial of radiotherapy. Cancer 2005; 103:320–8

    Article  PubMed  Google Scholar 

  4. Norton L, Massague J. Is cancer a disease of self-seeding? Nature Med 2006; 12:875–8

    Article  PubMed  CAS  Google Scholar 

  5. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Inv 2005; 115:44–55

    Article  CAS  Google Scholar 

  6. Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N. Metastatic breast carcinoma confined to bone. Portrait of a clinical entity. Cancer 2004; 101:1524–8

    Article  PubMed  Google Scholar 

  7. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 2006; 98:1285–91

    Article  PubMed  CAS  Google Scholar 

  8. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of Trastuzumab combined with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 study group. J Clin Oncol 2005; 23:4265–74

    Article  PubMed  CAS  Google Scholar 

  9. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006; 355:2733–43

    Article  PubMed  CAS  Google Scholar 

  10. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PFM, Spillane JB, Hopper JL, Martin TJ. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 2006; 66:2250–6

    Article  PubMed  CAS  Google Scholar 

  11. Talon I, Lindner V, Sourbier C, et al. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis 2006; 27:73–83

    Article  PubMed  CAS  Google Scholar 

  12. Saito H, Tsunenari T, Onuma E, et al. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Res 2005; 25:3817–23

    PubMed  CAS  Google Scholar 

  13. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database of Syst Rev 2005; 3

  14. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. Brit Med J 2005; 330:769–73

    Article  PubMed  CAS  Google Scholar 

  15. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003; 14:1234–40

    Article  PubMed  CAS  Google Scholar 

  16. Lequaglie C, Massone PB, Giudice G, Conti B. Gold standard for sternotomies and plastic reconstructions after resections for primary or secondary sternal neoplasms. Ann Surg Oncol 2002; 9:472–9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Breast Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Karl J. Sweeney MD FRCS (gen) & Tari King MD

  2. Departments of Surgery, Orthopedic Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Patrick J. Boland MD

Authors
  1. Karl J. Sweeney MD FRCS (gen)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick J. Boland MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tari King MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl J. Sweeney MD FRCS (gen).

Additional information

Authors’ Contribution: K. J. Sweeney: Clinical Breast Fellow; P. J. Boland: Attending Orthopedic Surgeon; T. King: Attending Breast Surgeon

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweeney, K.J., Boland, P.J. & King, T. The Management of Asymptomatic Skeletal Breast Cancer: A Paradigm Shift. Ann Surg Oncol 14, 2430–2431 (2007). https://doi.org/10.1245/s10434-007-9466-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9466-9

Search

Navigation